PROSTIN E2 Rx
Generic Name and Formulations:
Dinoprostone 20mg; per vaginal suppository.
Indications for PROSTIN E2:
For the termination of pregnancy from the 12th through the 20th gestational weeks. For the evacuation of the uterine contents in the management of missed abortion or intrauterine fetal death up to 28 weeks of gestational age. Management of nonmetastatic gestational trophoblastic disease (benign hydatidiform mole).
Insert one supp high into vagina. Remain in supine position for 10mins following insertion. May insert subsequent supp at 3–5hr intervals until abortion occurs. Continuous administration for more than 2 days is not recommended.
Acute pelvic inflammatory disease. Active cardiac, pulmonary, renal or hepatic disease.
Not indicated if fetus in utero has reached the stage of viability. Not for use in cervical ripening or other indication in patients with term pregnancy. Asthma. Hypo-or hypertension. Anemia. Jaundice. Diabetes. Epilepsy. History of cardiac, renal, or hepatic disease. Cervicitis. Infected endocervical lesions. Acute vaginitis. Compromised (scarred) uteri. Remove supp if hypersensitivity reaction is suspected. Pregnancy.
Concomitant other oxytocic agents: not recommended.
Vomiting, transient pyrexia (see full labeling re: PGEs induced pyrexia vs. endometritis pyrexia), diarrhea, nausea, headache, chills, transient decrease in BP; MI in patients with history of CVD, hypersensitivity.
Neurology Advisor Articles
- FDA Approves Aimovig for Migraine Prevention
- Sports-Related Concussion Outcomes Predicted With Serum Neurofilament Light
- FDA: Lamotrigine Linked to Potentially Life-Threatening Adverse Reaction
- Risk of Developing Multiple Sclerosis After HPV Vaccination
- Psychological Therapies May Help Older Adults With Chronic Pain
- Amyloid-Positivity Increases Risk for Cognitive Impairment in Dementia-Free Patients
- Valproic Acid-Related Adverse Fetal Outcomes May Be Linked to Placental Effects
- Risk of Dementia Up for Older Adults With Lowest Wealth
- Language Used in Medical Record Can Affect Patient Care
- Mortality in Alzheimer Disease Not Strongly Associated With Antipsychotics